Latest Robotics News

Page 2 of 26
Hydrix reported September-quarter revenue growth of 11.6% year on year and secured further medical and Defence milestones. But with $1.5 million in cash and reported funding covering only 1.30 quarters, the company still needs contract wins to convert into receipts and revenue.
Sophie Babbage
Sophie Babbage
29 Oct 2026
4DS Memory has completed its acquisition of Jenesys and appointed founder Jaspal Sarai as CEO, combining autonomous-systems software with its ReRAM technology. The company has A$6.6 million in quarter-end cash plus a further A$2 million placement, but has yet to secure a binding customer agreement.
Sophie Babbage
Sophie Babbage
29 Oct 2026
Appen has delivered its strongest quarterly result of FY26, with revenue rising 34% to US$73.9 million and underlying EBITDA increasing more than tenfold to US$10.3 million. Appen Global returned to profit while China continued to drive growth, although FY26 revenue is expected to land in the lower half of guidance.
Victor Sage
Victor Sage
29 Oct 2026
Titomic has strengthened its balance sheet with A$16.5 million in new equity and approval for a further US$10.3 million EXIM loan, while reporting more than A$11.8 million in orders since September. The progress comes with a sharper funding test: quarter-end cash was A$18.1 million after a A$10.4 million operating outflow, and the EXIM facility remains undrawn.
Victor Sage
Victor Sage
29 Oct 2026
Hydrix reported stronger contract momentum and launched a defence strategy in FY26, but revenue fell, cash burn increased and its statutory loss widened to $6.72 million. The auditor identified a material uncertainty over the company’s ability to continue as a going concern, despite a $5.2 million capital raising and planned debt conversions.
Sophie Babbage
Sophie Babbage
27 Oct 2026
icetana AI returned to revenue growth in FY26, with sales up 31% to $2.47 million and annual recurring revenue reaching $2.6 million. The company remains loss-making, but entered FY27 with stronger recurring revenue, new distribution channels and $4.79 million in cash.
Sophie Babbage
Sophie Babbage
27 Oct 2026
dorsaVi has commercially launched its first wearable capable of analysing movement and delivering feedback directly on-device, while its RRAM chip program moves into fabrication and testing. The progress comes alongside a post-quarter A$3.0 million capital raising, against quarter-end cash of $1.12 million and operating cash outflow of about $996,000.
Sophie Babbage
Sophie Babbage
23 Oct 2026
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
CurveBeam AI has secured its strongest first-quarter HiRise sales result, gained China regulatory clearance and raised A$7.35 million to fund the next stage of commercialisation. The progress comes alongside lower customer receipts and a reported 4.3 quarters of cash runway.
Victor Sage
Victor Sage
21 Oct 2026
icetana AI has started FY27 with a sharp lift in recurring revenue and quarterly sales, while its Antara Core platform reached its first commercial deployment. The progress came alongside higher operating cash outflows and a $3.9 million cash balance.
Sophie Babbage
Sophie Babbage
20 Oct 2026
XRF Scientific has delivered its strongest September quarter in years, with revenue rising 38% to $21.1 million and profit before tax climbing 30% to $4.4 million. Orbis growth, resilient consumables demand and the developing CGA business are giving the company several avenues for further expansion, although precious metals revenue included a low-margin one-off sale.
Victor Sage
Victor Sage
13 Oct 2026
Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.
Ada Torres
Ada Torres
13 Oct 2026

Browse the archive

Full archive